L-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL)
- 3 November 2009
- journal article
- research article
- Published by Elsevier BV in Journal of Controlled Release
- Vol. 139 (3), 182-189
- https://doi.org/10.1016/j.jconrel.2009.06.027
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Preliminary in vivo evaluation of the protein transduction domain‐modified ATTEMPTS approach in enhancing asparaginase therapyJournal of Biomedical Materials Research Part A, 2008
- PTD-modified ATTEMPTS system for enhanced asparaginase therapy: A proof-of-concept investigationJournal of Controlled Release, 2008
- Applications of carrier erythrocytes in delivery of biopharmaceuticalsJournal of Controlled Release, 2006
- Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo studyThe FASEB Journal, 2005
- Drug, enzyme and peptide delivery using erythrocytes as carriersJournal of Controlled Release, 2004
- Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (I): Preparation and characterizationAAPS PharmSci, 2001
- In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the MouseScience, 1999
- Stabilization of L-Asparaginase Modified with Comb-Shaped Poly(ethylene glycol) Derivatives, in vivo and in vitroBioconjugate Chemistry, 1994
- Asparaginase Entrapped in Red Blood Cells: Action and SurvivalScience, 1976
- L-Asparaginase and L-Asparagine MetabolismAnnual Review of Pharmacology, 1970